MARKET

BGNE

BGNE

Beigene Ltd
NASDAQ
172.85
+1.82
+1.06%
After Hours: 173.01 +0.16 +0.09% 18:44 05/17 EDT
OPEN
171.00
PREV CLOSE
171.03
HIGH
176.00
LOW
169.76
VOLUME
275.36K
TURNOVER
0
52 WEEK HIGH
245.74
52 WEEK LOW
126.97
MARKET CAP
18.07B
P/E (TTM)
-22.8375
1D
5D
1M
3M
1Y
5Y
BeiGene (BGNE) Shares Cross Above 200 DMA
NASDAQ · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Sanara MedTech (SMTI)
TipRanks · 4d ago
BeiGene Performance Analysis: A Hold Rating with Cautious Optimism Amidst Competitive Pressures
TipRanks · 4d ago
BeiGene To Highlight New Hematology Portfolio And Pipeline Data At EHA2024, June 13-16, 2024
Benzinga · 5d ago
Leap Therapeutics: The DisTinGuish Trial Provides A Near-Term Catalyst
Leap Therapeutics is developing a drug with potential in multiple types of cancer. The company's drug DKN-01 is an anti-DKK1 monoclonal antibody in clinical trials for colorectal, esophagogastric and endometrial cancer. LPTX's DisTinGuish trial in gastric cancer is set to produce initial data in mid-2024. Part C of the DisT in Guish trial is a near-term catalyst for the company.
Seeking Alpha · 6d ago
Merck discontinues testing of experimental skin cancer combo therapy
Healthcare Merck discontinues testing of experimental skin cancer combo therapy. Merck has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial. The drugmaker says it is unlikely the trial could achieve a statistically significant improvement in recurrence-free survival.
Seeking Alpha · 6d ago
Weekly Report: what happened at BGNE last week (0506-0510)?
Weekly Report · 6d ago
BeiGene’s Soaring Sales and Path to Profitability Reinforce Buy Rating
TipRanks · 05/10 06:08
More
About BGNE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Webull offers Beigene Ltd (ADR) stock information, including NASDAQ: BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BGNE stock methods without spending real money on the virtual paper trading platform.